Radiation-Free path for young breast cancer patients? trial tests skipping therapy
NCT ID NCT07762924
First seen Aug 13, 2026 · Last updated Aug 14, 2026 · Updated 1 time
Summary
This trial is testing whether young women under 40 with a very early, low-risk form of breast cancer called ductal carcinoma in situ (DCIS) can safely avoid radiation therapy after having breast-conserving surgery. Instead of radiation, participants will be closely monitored, and some may take hormone-blocking medication. The study will track how many women experience a recurrence in the same breast over five years to see if skipping radiation is a safe option.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Omission of adjuvant radiotherapy, with close surveillance and optional endocrine therapy
- What this could lead to
- If successful, this could show that some young women with low-risk DCIS can safely skip radiation, avoiding side effects and reducing treatment burden.
- What could go wrong
- This is a phase II trial, so results are preliminary. Skipping radiation may increase the risk of breast cancer recurrence, and the long-term safety is not yet established.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DUCTAL CARCINOMA IN SITU, DCIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fudan University Shanghai Cancer Center
RECRUITINGShanghai, 200032, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.